Posts Tagged ‘Healthcare’

ASX Company News: Allied Healthcare To Supply Software To North Queensland Hospital

Thursday, November 8th, 2012

Australian biomedical company Allied Healthcare Group (AHZ) has secured a five year contract to supply an infusion management platform to a North Queensland hospital. Allied will supply the Swiss-made Arcomed infusion management system after Mater Health Service North Queensland (MHSNQ), awarded the company the contract.

Lee Rodne, Group Managing Director, Allied Healthcare Group said the contract was the latest in a period of strong sales growth and it validated efforts to bring the technology to Australia. “This robust and cutting-edge device represents the latest in infusion management technology, which is designed to improve both hospital efficiency and clinical outcomes for patients by using data management to ensure patients receive the correct medication at the correct time” Mr  Rodne said. “This five year supply contract also signals a growing recognition of Allied as a leading provider of innovative medical products and technologies, to Australian and New Zealand hospitals and healthcare facilities.”

Allied Healthcare Group Limited (AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical Sales and Marketing division. The Company has assets from research & development, clinical development as well as sales and marketing of medical devices and technologies.

www.alliedhealthcaregroup.com.au

 

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Ellex Medical Lasers To Manufacture Parts For Signostics

Friday, November 2nd, 2012

Ellex Medical Lasers Limited (ELX), a global leader in ophthalmic laser and ultrasound technology, announced that it has been awarded a contract by Signostics Limited, a pioneer in the development of hand-held medical ultrasound devices, to manufacture the critical sub-assembly of the Signostics ultrasound device, Signos RT.

According to Ellex CEO Tom Spurling, the agreement with Signostics is an important initiative in the Company’s stated strategy to identify new, complementary revenue streams, which leverage its existing manufacturing and engineering capabilities. “Whilst we remain committed to maintaining and improving our position as a leader in the global ophthalmic laser and imaging market, this is an important opportunity to ensure the optimal utilisation of our highly skilled manufacturing team and to diversify our earnings”, said Mr. Spurling.

Ellex Medical Lasers Limited (ELX) is a global leader in the design and manufacture of ophthalmic laser and ultrasound systems used by ophthalmologists to diagnose and treat eye disease. Signostics Limited was established in Adelaide, South Australia, in 2005 to be a world leader in fast and affordable point-of-care ultrasound medical devices. Signos RT is a new-generation, portable, hand-held ultrasound device designed for point-of-care use by medical practitioners in a number of clinical settings, including primary care medicine, rural and remote medicine, midwifery and bladder scanning and emergency and intensive care medicine.

www.ellex.com

 

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Phosphagenics Licenses Injectable Antibiotic Product To Agila In India

Wednesday, October 31st, 2012

Australian drug delivery technology company Phosphagenics Limited (POH) has licensed an injectable antibiotic product, harnessing its proprietary TPM® platform technology, to Agila Specialties Private Limited (Agila). Agila is a wholly owned subsidiary of the listed Indian pharmaceutical company, Strides Arcolab (Strides).

Agila has one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world with its operations spread over nine world-class manufacturing facilities around the globe. The company is focused on developing and commercialising new products for key therapeutic markets targeting anti- infectives, oncology, central nervous system (CNS), gastro-intestinal (GI), ophthalmics and peptides.

Under the terms of the exclusive global license agreement, Phosphagenics will license the TPM® technology to Agila for its use in an antibiotic injectable product. Agila will be responsible for the development and pay the costs required to register and commercialise the product including all necessary clinical studies. Phosphagenics will receive an upfront payment as well as undisclosed royalties based on net sales. The size of the antibiotic injectables market is several billion dollars annually.

Company CEO, Dr Esra Ogru, said this agreement demonstrates the versatility of the TPM® platform technology, paving the way for further opportunities in the injectable market. “Strides and its subsidiary, Agila, have state-of-the-art manufacturing capabilities and have had tremendous success in bringing new products to market. This will be the first time TPM® will be used in an injectable formulation.”

www.phosphagenics.com

 

Post to Twitter

Tags: , , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Agenix Licenses Diagnostic Technology

Friday, October 26th, 2012

Agenix Limited (AGX) announced it had entered an agreement with Tyrian Diagnostics Limited (TDX) to license its rapid point-of-care human diagnostic technology in a share exchange transaction. Under the terms of the agreement, Agenix will license exclusive world-wide royalty free rights to the human health application for Tyrian’s proprietary DiagnostIQ® rapid point-of-care test platform. In return, Agenix will provide Tyrian with Agenix shares to the value of $0.5 million payable in installments to be completed by June 2014. The DiagnostIQ® platform comprises a patented disposable test device which can be used for various applications either alone or together with the DiagnostIQ® Reader for various human, animal and agricultural applications to determine action to be taken at the PoC (human and veterinary tests) or PoN (agricultural and environmental tests). Agenix has licensed the rights to develop the DiagnostIQ® platform for human health applications and aims to develop the technology into a micro-array device so that it will process multiple human health diagnostic tests on the one system.

Agenix Limited Chairman and Chief Executive Officer Nicholas Weston said, “This acquisition advances our product pipeline and adds to our human health diagnostics business. “We now have a platform for human health array and micro-array technology developers globally, as well as a medical device product for our expanding China business.” Tyrian Limited Chairman, Roger Amos said the licence agreement with Agenix was part of the company’s continued efforts by Tyrian to monetise its diagnostic testing assets following the recent company restructuring. It follows a 2011 licence to SpeeDx Pty Ltd for active TB testing approaches outside of the antibody field.

Agenix is a public, clinical-stage company focused on the discovery and development of innovative monoclonal antibody blood clot diagnostics, and small molecule drugs for the treatment of hepatitis B and other serious diseases.

www.agenix.com

 

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Resonance Health Secures Two New Contracts

Wednesday, October 24th, 2012

Resonance Health (RHT) has executed two multi-year contracts with a pharmaceutical company to provide FerriScan services, for an undisclosed sum. One contract will involve Resonance Health working with up to 15 MRI facilities that will image patients participating in the clinical trial. Resonance Health will provide FerriScan image analysis services to measure liver iron concentration and a cardiac iron assessment for these patients. Resonance Health recently gained regulatory approval for the measurement of a parameter called cardiac T2* which provides  an indirect assessment of cardiac iron overload. In the second contract Resonance Health has been engaged to work with up to 20 MRI facilities across a number of countries and will provide a range of services to support the use of FerriScan in this clinical trial.

Resonance Health is pleased with the growing uptake of the Company’s cardiac iron image analysis  services and the medical community’s recognition of FerriScan’s superior performance for assessing liver iron concentration. Resonance Health Ltd (RHT) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health’s patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.

www.resonancehealth.com

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Bluechiip Enters Joint Venture For Healthcare Tracking With Inpeco

Monday, October 22nd, 2012

Bluechiip Limited (BCT) announced it has signed a Term Sheet to execute a Collaborative Co-Development Agreement with Swiss company Inpeco SA which allows both parties to collaborate to develop Inpeco products which integrate Bluechiip’s technology. Based in Lugano, Switzerland, Inpeco designs and manufactures automation systems for the total automation of clinical laboratories, so improving and simplifying biological sample processing. Inpeco works closely with some of the world’s largest and most advanced healthcare and technology companies. Inpeco’s solutions operate in more than 500 clinical laboratories around the world, making biological sample workflow an efficient and fast automatic process.

“We are delighted that Inpeco, a leader in its field, is looking at integrating Bluechiip’s tracking technology in its products,” said Bluechiip Limited CEO and Managing Director Brett Schwarz. “Integrating the bluechiip® technology into the robotics of automated laboratory equipment is a  critical step in the movement away from manual systems.” Dr Jason Chaffey, Bluechiip Limited Chief Technical Officer (CTO), said “We are confident that our technology will be valuable in automated equipment used in life sciences where samples are being stored in ultra-cold environments like liquid nitrogen. Current tracking and labelling techniques of labels and barcodes do not operate well in these ultra-low temperature environments, especially when frost is prevalent. It is also critical to be able to monitor the temperature of these valuable samples, which only the bluechiip® tracking technology can do.”

Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and  microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification). The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Inpeco is dedicated to design and manufacture automation systems to improve and simplify biological sample processing in clinical laboratories. Inpeco offers OEM solutions to its strategic, international partners, and also acts as direct supplier, providing end-users (i.e. public and private laboratories) with the Inpeco’s branded FlexLab automation system.

www.bluechiip.com

 

Post to Twitter

Tags: , , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Universal Biosensors Secures Siemens Blood Test Contract

Monday, September 24th, 2012

Universal Biosensors (UBI) has strengthened its partnership with Siemens Healthcare Diagnostics, announcing it has signed a long term supply and manufacturing agreement which will see UBI become the exclusive manufacturer of three test strips currently being jointly developed for the point-of-care (POC) coagulation testing market.

Universal Biosensors is developing with Siemens, a range of products for the POC coagulation testing market. The signing of the supply and manufacturing agreement represents an important milestone for Universal Biosensors in the lead up to the launch of the first product in this range, a PT-INR testing system used to monitor the application of the anti-coagulant therapy Warfarin, which is expected to be commercially available in 2013.

Apart from the ongoing R&D milestone payments to be received from Siemens, Universal Biosensors will generate a return on its R&D investment in coagulation testing via its gross margin earned on the manufacture and supply of test strips to Siemens. In addition, consistent with the collaboration philosophy, Universal Biosensors will share in incremental profits generated by Siemens on sales of these products that exceed their current forecasts by a specified amount.

UBI CEO Paul Wright said, “The signing of this Supply Agreement is a major step forward in our relationship with Siemens and towards our shared vision for bringing a range of novel handheld analysers to the POC coagulation testing market. Universal Biosensors will leverage its existing infrastructure to offer world-class manufacturing support to Siemens and create a new and important long term earnings stream for our business.”

www.universalbiosensors.com

Post to Twitter

Tags: , , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Atcor Medical Secures New Contract

Tuesday, August 14th, 2012

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which  measures central aortic blood pressures and arterial stiffness noninvasively, announced that it has signed a contract to supply AtCor Medical’s new SphygmoCor XCEL systems and clinical trial support services to a major international pharmaceutical company. SphygmoCor XCEL measures brachial and central aortic blood pressure simultaneously and was launched by AtCor Medical in May 2012. The value of the contract is approximately US$1.1 million.

Duncan Ross, CEO of AtCor Medical said, “We are pleased to have secured this contract and delighted the customer has decided to use the new XCEL system, which greatly enhances ease of use while maintaining central aortic blood pressure waveform fidelity and data quality. XCEL further consolidates AtCor Medical‘s gold standard position with both researchers and clinicians.  Our product quality is matched by our reputation as a highly reliable provider of clinical trial support services to the pharmaceutical sector.”

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,700 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 600 peer-reviewed studies published in leading medical journals.

www.atcormedical.com

Post to Twitter

Tags: , , ,
Posted in ASX Company News | No Comments

ASX Company News: Novogen To Merge With Kai Medical

Monday, July 30th, 2012

Novogen (NRT) announced that it has entered into a merger agreement with Kai Medical, a United States based company, incorporated in Delaware, whose business is focused on sleep apnoea therapy devices and wireless respiration monitoring technology. The agreement is subject to a number of conditions including completion of due diligence and shareholder approval. A summary of the key terms of the merger agreement including the conditions precedent is set out in the attachment to this announcement.

“We are very pleased to be able to enter into a relationship with Kai Medical that provides Novogen shareholders with an opportunity to participate in the growth and success of Kai Medical’s revolutionary sleep apnoea therapy device”, said William D Rueckert, Chairman of the Board for Novogen. He continued, “the sleep apnoea market, Worldwide is a rapidly growing market with tremendous opportunities for companies like Kai that have a product with a distinct performance advantages. There is a clear unmet need for patients with this condition for a convenient and effective therapy.” Bob Nakata, CEO of Kai Medical added, “Kai Medical has recently received its CE Mark for Kai Apnea, which is the key regulatory approval needed for sales in most of the world. Kai Apnea is more comfortable to use and will likely have higher compliance than most other sleep apnoea devices. I believe that this will lead to strong growth in the coming years and am pleased that we can share this progress with Novogen shareholders through this transaction.”

In addition to the merger agreement with Kai, Novogen announced that in advance of the merger with Kai Medical and subject to shareholder approval, it will undertake a capital reduction and in specie distribution to the Novogen shareholders of the shares of MEI Pharma, Inc., (formerly known as Marshall Edwards, Inc.) that it owns.

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc.  Kai Medical develops and markets medical devices for sleep apnoea therapy and devices to measure and monitor respiration wirelessly, with no contact, and from a distance. Kai Medical is based in Honolulu, Hawaii USA.

www.novogen.com

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Sonic Healthcare To Acquire Healthscope Pathology Business

Thursday, May 17th, 2012

Sonic Healthcare Limited (SHL) is pleased to announce that it has reached binding agreements to acquire the New South Wales/ACT, Queensland and Western Australian pathology businesses of Healthscope. The three businesses have combined annualised revenue of ~A$105 million. The total purchase price of A$100 million (cash & debt free) will be funded in AUD from Sonic’s existing debt facilities, and represents a prospective EBITDA multiple of less than 5 times on a post-synergy basis. Synergies, which have been conservatively forecast, are expected to be fully realised by the end of the first six months following completion of the acquisitions, from which stage the acquisitions will be accretive to both Sonic’s earnings per share and return on invested capital.

Sonic’s CEO, Dr Colin Goldschmidt said: “The acquisition of these businesses will be value accretive for Sonic’s shareholders and we will be pleased to welcome the pathologists, management and staff of the Healthscope businesses into Sonic’s global team”.

www.sonichealthcare.com

Post to Twitter

Tags: , , , , , , ,
Posted in ASX Company News | No Comments

« Older Entries